(Q24200496)

1

0 references

Luning Wang

2

0 references

Si-Yan Zhan

3

0 references

Yinyin Xia

Cochrane Database of Systematic Reviews

4

0 references

publication date

18 April 2012

0 references

published in

0 references

cites work

Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008127.PUB3

Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon beta

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008127.PUB3

Regulatory CD56(bright) natural killer cells mediate immunomodulatory effects of IL-2Ralpha-targeted therapy (daclizumab) in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008127.PUB3

Effect of anti-CD25 antibody daclizumab in the inhibition of inflammation and stabilization of disease progression in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008127.PUB3

Intrathecal effects of daclizumab treatment of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008127.PUB3

Regulatory T cells are reduced during anti-CD25 antibody treatment of multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008127.PUB3

Daclizumab phase II trial in relapsing and remitting multiple sclerosis: MRI and clinical results

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008127.PUB3

Multiple sclerosis therapies in pediatric patients with refractory multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008127.PUB3

Selective modulation of human natural killer cells in vivo after prolonged infusion of low dose recombinant interleukin 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008127.PUB3

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008127.PUB3

Immunopathogenesis and immunotherapy of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008127.PUB3

Anti-CD25 (daclizumab) monoclonal antibody therapy in relapsing-remitting multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008127.PUB3

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008127.PUB3

Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008127.PUB3

New diagnostic criteria for multiple sclerosis: guidelines for research protocols

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008127.PUB3

The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008127.PUB3

Daclizumab in treatment of multiple sclerosis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008127.PUB3

Treatment of multiple sclerosis with an anti-interleukin-2 receptor monoclonal antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008127.PUB3

inferred from DOI database lookup

7 January 2021

based on heuristic

Biology of the interleukin-2 receptor

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008127.PUB3

inferred from DOI database lookup

7 January 2021

based on heuristic

Cutting edge: in vivo blockade of human IL-2 receptor induces expansion of CD56(bright) regulatory NK cells in patients with active uveitis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008127.PUB3